The Steroid Receptor Coactivators are master regulators of nuclear receptors. Specifically, SRC-2 serves as a regulator of male reproduction and is preferentially expressed in Sertoli cells. SRC-2'^'males are able to produce sperm at tlie onset of pulserty, but quickly become infertile. This loss of male fertility is due to defects in Sertoli cell function which raises the possibility that effective anti-SRC-2 small molecule antagonists (SMAs) can be developed as male contraceptive agents. Gossypol was tested as a male contraceptive agent in ~10,000 men in China and was found to be well tolerated at the doses tested and was effective as an anti-fertility agent 99% of the time. However, due to the risic of inreversible infertility and hyperkalemia, its use as a contraceptive agent was abandoned. Interestingly, gossypol treated animals develop defects in Sertoli cell biology that are strikingly similar to that seen in SRC-2'''mice. Genetic disruption of SRC-2 and gossypol treatment both result in teratozoospermia and age dependent-iike testicular degeneration. Sertoli cells of both SRC-2'''and gossypol-treated mice accumulate lipid, indicative of a common defect in Sertoli cell metabolism. In preliminary screening for SRC-2 SMIs in our laboratory, we have identified several gossypol derivatives that can disrupt the coactivator function of SRC-2. We have already completed high throughput screening campaigns for SMAs against SRC-1 and SRC-3 and are initiating a similar effort for SRC-2 as well. Because of the strong link between SRC-2, gossypol, Sertoli cell biology and male infertility, we propose to screen and characterize new SRC-2 S M ^ as a novel class of male contraceptive agents. In conjunction with support for compound chemistry that exists in this U54 application, we expect to generate SRC-2-targeting male contraceptive agents with the potential to be clinically viable.

Public Health Relevance

Small molecule antagonist screens to identify agents that can dismpt the function of steroid receptor coactivator 2 have identified a number of gossypol derivates as tool compounds. Because gossypol is a male anti-fertility agent that disrupts Sertoli cell function and produces effects that phenocopy defects in male reproduction observed in SRC-2'''mice, this proposal aims to develop a new class of male contraceptive agents, based on their ability to target SRC-2.

National Institute of Health (NIH)
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZHD1)
Program Officer
Lee, Min S
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Baylor College of Medicine
Anatomy/Cell Biology
Schools of Medicine
United States
Zip Code
Hai, Lan; Szwarc, Maria M; He, Bin et al. (2018) Uterine function in the mouse requires speckle-type poz protein. Biol Reprod 98:856-869
Rohira, Aarti D; Yan, Fei; Wang, Lei et al. (2017) Targeting SRC Coactivators Blocks the Tumor-Initiating Capacity of Cancer Stem-like Cells. Cancer Res 77:4293-4304
Szwarc, Maria M; Kommagani, Ramakrishna; Peavey, Mary C et al. (2017) A bioluminescence reporter mouse that monitors expression of constitutively active ?-catenin. PLoS One 12:e0173014
Rohira, Aarti D; Lonard, David M (2017) Steroid receptor coactivators present a unique opportunity for drug development in hormone-dependent cancers. Biochem Pharmacol 140:1-7
Wang, Lei; Lonard, David M; O'Malley, Bert W (2016) The Role of Steroid Receptor Coactivators in Hormone Dependent Cancers and Their Potential as Therapeutic Targets. Horm Cancer 7:229-35
Song, Xianzhou; Chen, Jianwei; Zhao, Mingkun et al. (2016) Development of potent small-molecule inhibitors to drug the undruggable steroid receptor coactivator-3. Proc Natl Acad Sci U S A 113:4970-5
Lonard, David M; O'Malley, Bert W (2016) Molecular Pathways: Targeting Steroid Receptor Coactivators in Cancer. Clin Cancer Res 22:5403-5407
Song, Xianzhou; Zhang, Chengwei; Zhao, Mingkun et al. (2015) Steroid Receptor Coactivator-3 (SRC-3/AIB1) as a Novel Therapeutic Target in Triple Negative Breast Cancer and Its Inhibition with a Phospho-Bufalin Prodrug. PLoS One 10:e0140011
Wang, Lei; Yu, Yang; Chow, Dar-Chone et al. (2015) Characterization of a Steroid Receptor Coactivator Small Molecule Stimulator that Overstimulates Cancer Cells and Leads to Cell Stress and Death. Cancer Cell 28:240-52
Wang, Ying; Lonard, David M; Yu, Yang et al. (2014) Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1. Cancer Res 74:1506-1517

Showing the most recent 10 out of 11 publications